Myosin ATPase inhibition fails to rescue the metabolically dysregulated proteome of nebulin‐deficient muscle
The Journal of Physiology · 2024
DOI: 10.1113/jp286870 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physiology, 2024. Verfasst von Jenni Laitila und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Myopathies, Nemaline, Proteome, Muscle Proteins, Muscle, Skeletal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation, HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Novo Nordisk Fonden.
Abstract (Originalsprache)
Nemaline myopathy (NM) is a genetic muscle disease, primarily caused by mutations in the NEB gene ( NEB‐ NM) and with muscle myosin dysfunction as a major molecular pathogenic mechanism. Recently, we have observed that the myosin biochemical super‐relaxed state was significantly impaired in NEB ‐NM, inducing an aberrant increase in ATP consumption and remodelling of the energy proteome in diseased muscle fibres. Because the small‐molecule Mavacamten is known to promote the myosin super‐relaxed state and reduce the ATP demand, we tested its potency in the context of NEB ‐NM. We first conducted in vitro experiments in isolated single myofibres from patients and found that Mavacamten successfully reversed the myosin ATP overconsumption. Following this, we assessed its short‐term in vivo effects using the conditional nebulin knockout (c Neb KO) mouse model and subsequently performing global proteomics profiling in dissected soleus myofibres. After a 4 week treatment period, we observed a remodelling of a large number of proteins in both c Neb KO mice and their wild‐type siblings. Nevertheless, these changes were not related to the energy proteome, indicating that short‐term Mavacamten treatment is not sufficient to properly counterbalance the metabolically dysregulated proteome of c Neb KO mice. Taken together, our findings emphasize Mavacamten potency in vitro but challenge its short‐term efficacy in vivo . image Key points No cure exists for nemaline myopathy, a type of genetic skeletal muscle disease mainly derived from mutations in genes encoding myofilament proteins. Applying Mavacamten, a small molecule directly targeting the myofilaments, to isolated membrane‐permeabilized muscle fibres from human patients restored myosin energetic disturbances. Treating a mouse model of nemaline myopathy in vivo with Mavacamten for 4 weeks, remodelled the skeletal muscle fibre proteome without any noticeable effects on energetic proteins. Short‐term Mavacamten treatment may not be sufficient to reverse the muscle phenotype in nemaline myopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Centre of Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, MO, USA.
- The Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland and Department of Medical and Clinical Genetics, Medicum, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
- Copenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Neuromuscular and Ataxias Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
ORCID-Profile: Natasha Ranu, John Vissing, Juan Jesus Vilchez, Julien Ochala
Förderung
- Novo Nordisk Foundation
- HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Novo Nordisk Fonden
Zitieren
APA
Laitila, J., Seaborne, R. A. E., Ranu, N., Kolb, J. S., Wallgren-Pettersson, C., Witting, N., Vissing, J., Vilchez, J. J., Zanoteli, E., Palmio, J., Huovinen, S., Granzier, H., & Ochala, J. (2024). Myosin ATPase inhibition fails to rescue the metabolically dysregulated proteome of nebulin‐deficient muscle. The Journal of Physiology. https://doi.org/10.1113/jp286870
Vancouver
Laitila J, Seaborne RAE, Ranu N, Kolb JS, Wallgren-Pettersson C, Witting N, et al. Myosin ATPase inhibition fails to rescue the metabolically dysregulated proteome of nebulin‐deficient muscle. The Journal of Physiology. 2024. doi:10.1113/jp286870
BibTeX
@article{Laitila2024,
author = {Laitila, Jenni and Seaborne, Robert A E and Ranu, Natasha and Kolb, Justin S and Wallgren-Pettersson, Carina and Witting, Nanna and Vissing, John and Vilchez, Juan Jesus and Zanoteli, Edmar and Palmio, Johanna and Huovinen, Sanna and Granzier, Henk and Ochala, Julien},
title = {Myosin ATPase inhibition fails to rescue the metabolically dysregulated proteome of nebulin‐deficient muscle},
journal = {The Journal of Physiology},
year = {2024},
doi = {10.1113/jp286870}
}
EUVIMED